更年期、绝经激素治疗与阿尔茨海默病的新视野:当前见解与未来方向
综述指出绝经激素治疗对阿尔茨海默病及全因痴呆风险的影响受启动时机、绝经年限和制剂类型影响;65岁以上女性随机临床试验显示痴呆风险增加,中年观察性研究提示单用雌激素与风险降低相关而雌孕激素联合结果不一;作者主张用阿尔茨海默病生物标志物评估早期特异性结局。
要点
- 65岁及以上绝经后女性绝经激素治疗随机临床试验显示痴呆风险增加。
- 中年观察性研究提示单用雌激素与阿尔茨海默病及痴呆风险降低相关,雌孕激素联合结果不一。
- 绝经激素治疗相关乳腺癌、卒中和静脉血栓栓塞风险通常被认为罕见(<10例/10000名女性)。
核心结论
- 总体文献支持重新关注将绝经激素治疗作为女性特异性、时间敏感性的阿尔茨海默病风险降低策略进行研究,这对将累积数据用于阿尔茨海默病预防的临床决策至关重要。
研究设计与样本
- 综述汇总随机临床试验与观察性研究,讨论采用阿尔茨海默病生物标志物评估绝经激素治疗相关早期阿尔茨海默病特异性结局的方法。
主要发现
- 在65岁及以上绝经后女性中开展的绝经激素治疗随机临床试验显示痴呆风险增加。
- 中年随机临床试验缺乏,观察性研究提供证据表明中年单用雌激素治疗与阿尔茨海默病和痴呆风险降低相关,而雌孕激素联合治疗与更多变的结果相关。
- 现有研究异质性大,传统终点可能无法充分评估绝经激素治疗预防阿尔茨海默病的潜力。
- 绝经激素治疗相关风险包括乳腺癌、卒中和静脉血栓栓塞,通常被认为罕见(<10例/10000名女性)。
临床怎么用
- 从临床角度看,绝经激素治疗可能降低痴呆风险的发现值得考虑,因为现有乙酰胆碱酯酶抑制剂和美金刚缺乏预防效力,且用于一级或二级预防的疫苗尚不可用。
- 总体文献支持重新关注将绝经激素治疗作为女性特异性、时间敏感性的阿尔茨海默病风险降低策略进行研究,这对将累积数据用于阿尔茨海默病预防的临床决策至关重要。
局限性
- 现有研究异质性大,传统终点可能无法充分评估绝经激素治疗预防阿尔茨海默病的潜力。
- 中年随机临床试验缺乏。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Accumulating evidence suggests that the effects of menopausal hormone therapy (MHT) on risk of Alzheimer disease (AD) and all-cause dementia are influenced by timing of initiation relative to age, time-since-menopause, and the type of formulation. Randomized clinical trials (RCTs) of MHT conducted in postmenopausal women ages 65 and older indicated an increased risk of dementia. While RCTs conducted in midlife are lacking, observational research has provided evidence for associations between midlife estrogen-only therapy (ET) use and a reduced risk of AD and dementia, whereas estrogen-progestogen therapy (EPT) was associated with more variable outcomes. However, existing studies are heterogenous, and conventional endpoints might not adequately assess MHT's potential for AD prevention. Herein, several approaches are being discussed, and the case is being made for utilizing AD biomarkers for assessment of early, AD-specific outcomes in relation to MHT use. From a clinical standpoint, findings that MHT may lower dementia risk warrant consideration as existing therapies like acetylcholinesterase inhibitors and memantine lack preventative efficacy, and vaccines for primary or secondary prevention are not yet available. MHT-associated risks, including breast cancer, stroke and venous thromboembolism, are generally considered rare (<10 events/10 000 women). Overall, the literature supports renewed research interest in evaluating MHT as a female-specific, time-sensitive approach for AD risk reduction, which is key to applying cumulated data in clinical decision making concerning AD prevention.
引用
- Mosconi L, Nerattini M, Williams S, et al. New Horizons in Menopause, Menopausal Hormone Therapy, and Alzheimer's Disease: Current Insights and Future Directions. J Clin Endocrinol Metab. 2025. PMID: 39815764. doi:10.1210/clinem/dgaf026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。